PMID- 23074118
OWN - NLM
STAT- MEDLINE
DCOM- 20130314
LR  - 20211021
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 53
IP  - 6
DP  - 2012 Nov 1
TI  - Gamma linolenic acid exerts anti-inflammatory and anti-fibrotic effects in 
      diabetic nephropathy.
PG  - 1165-75
LID - 10.3349/ymj.2012.53.6.1165 [doi]
AB  - PURPOSE: This study was undertaken to investigate the effects of gamma linolenic 
      acid (GLA) on inflammation and extracellular matrix (ECM) synthesis in mesangial 
      and tubular epithelial cells under diabetic conditions. MATERIALS AND METHODS: 
      Sprague-Dawley rats were intraperitoneally injected with either a diluent [n=16, 
      control (C)] or streptozotocin [n=16, diabetes (DM)], and eight rats each from 
      the control and diabetic groups were treated with evening primrose oil by gavage 
      for three months. Rat mesangial cells and NRK-52E cells were exposed to medium 
      containing 5.6 mM glucose and 30 mM glucose (HG), with or without GLA (10 or 100 
      muM). Intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant 
      protein-1 (MCP-1), and fibronectin (FN) mRNA and protein expression levels were 
      evaluated. RESULTS: Twenty-four-hour urinary albumin excretion was significantly 
      increased in DM compared to C rats, and GLA treatment significantly reduced 
      albuminuria in DM rats. ICAM-1, MCP-1, FN mRNA and protein expression levels were 
      significantly higher in DM than in C kidneys, and these increases were 
      significantly abrogated by GLA treatment. In vitro, GLA significantly inhibited 
      increases in MCP-1 mRNA expression and protein levels under high glucose 
      conditions in HG-stimulated mesangial and tubular epithelial cells (p<0.05, 
      respectively). ICAM-1 and FN expression showed a similar pattern to the 
      expression of MCP-1. CONCLUSION: GLA attenuates not only inflammation by 
      inhibiting enhanced MCP-1 and ICAM-1 expression, but also ECM accumulation in 
      diabetic nephropathy.
FAU - Kim, Do-Hee
AU  - Kim DH
AD  - Department of Internal Medicine, Yonsei University College of Medicine, 50 
      Yonsei-ro, Seodaemun-gu, Seoul, Korea.
FAU - Yoo, Tae-Hyun
AU  - Yoo TH
FAU - Lee, Soon Ha
AU  - Lee SH
FAU - Kang, Hye Young
AU  - Kang HY
FAU - Nam, Bo Young
AU  - Nam BY
FAU - Kwak, Seung Jae
AU  - Kwak SJ
FAU - Kim, Jwa-Kyung
AU  - Kim JK
FAU - Park, Jung Tak
AU  - Park JT
FAU - Han, Seung Hyeok
AU  - Han SH
FAU - Kang, Shin-Wook
AU  - Kang SW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Fibronectins)
RN  - 0RBV727H71 (alpha-Linolenic Acid)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Blotting, Western
MH  - Chemokine CCL2/genetics/metabolism
MH  - Diabetic Nephropathies/*drug therapy/*metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Fibronectins/genetics/metabolism
MH  - Intercellular Adhesion Molecule-1/genetics/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Real-Time Polymerase Chain Reaction
MH  - alpha-Linolenic Acid/*therapeutic use
PMC - PMC3481382
COIS- The authors have no financial conflicts of interest.
EDAT- 2012/10/18 06:00
MHDA- 2013/03/15 06:00
PMCR- 2012/11/01
CRDT- 2012/10/18 06:00
PHST- 2012/10/18 06:00 [entrez]
PHST- 2012/10/18 06:00 [pubmed]
PHST- 2013/03/15 06:00 [medline]
PHST- 2012/11/01 00:00 [pmc-release]
AID - 2012111165 [pii]
AID - 10.3349/ymj.2012.53.6.1165 [doi]
PST - ppublish
SO  - Yonsei Med J. 2012 Nov 1;53(6):1165-75. doi: 10.3349/ymj.2012.53.6.1165.